nach oben

Erschienen in:

21.04.2016 | B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)

Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides

verfasst von: Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Cutaneous lymphomas (CL) are a heterogeneous group of neoplasms characterized with clinical and histopathological variation, as well as overlap with benign dermatoses. Diagnosis and treatment of CLs is challenging and often requires a multidisciplinary approach. However, prognostic knowledge of these conditions and awareness of treatment options can help optimize appropriate use of available regimens, thereby improving care for patients. Here, we review the most recent literature and outline treatment themes for managing patients with cutaneous B-cell and T-cell lymphomas other than mycosis fungoides.

Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.PubMedCrossRef

Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol. 2008;30(5):425–30.PubMedCrossRef

Fujiwara M, Morales AV, Seo K, Kim YH, Arber DA, Sundram UN. Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient. Am J Dermatopathol. 2013;35(1):11–8.

Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas. J Mol Diagn. 2000;2(1):5–10.PubMedPubMedCentralCrossRef

Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol. 1985;119(2):315–25.PubMedPubMedCentral

Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–61.PubMed

Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):576–81.PubMedCrossRef

Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):59–67.PubMedCrossRef

Wolf P, Cerroni L, Smolle J, Kerl H. PUVA-induced lymphomatoid papulosis in a patient with mycosis fungoides. J Am Acad Dermatol. 1991;25(2):422–6.PubMedCrossRef

10.

Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34(3):470–81.PubMedCrossRef

11.

Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206(2):142–7.PubMedCrossRef

12.

Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.PubMedCrossRef

13.

Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973–80.PubMedCrossRef

14.

Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049–58.PubMedCrossRef

15.

Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667–74.PubMedCrossRef

16.

Parrilla Castillar ER, Jaffe ES, Said J, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.CrossRef

17.

Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23:574–80.PubMedPubMedCentralCrossRef

18.

Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173–81.PubMedCrossRef

19.

Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.PubMedPubMedCentralCrossRef

20.

Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–22.PubMedCrossRef

21.

Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol Clin. 2008;26(4):529–40. viii.PubMedCrossRef

22.

Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol. 2004;35(2):231–9.PubMedCrossRef

23.

Paulli M, Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica. 2004;89(11):1372–88.PubMed

24.

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2013;24 Suppl 6:vi149–54.CrossRef

25.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Vol 2. Lyon, France: International Agency for Research on Cancer; 2008.

26.

Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404–13.PubMedCrossRef

27.

Matsue K, Itoh M, Tsukuda K, Miyazaki K, Kokubo T. Successful treatment of cytophagic histiocytic panniculitis with modified CHOP-E. Cyclophosphamide, adriamycin, vincristine, predonisone, and etoposide. Am J Clin Oncol. 1994;17(6):470–4.PubMedCrossRef

28.

Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplant. 2006;38(12):821–2.PubMedCrossRef

29.

Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk lymphoma. 2006;47(10):2250–2.PubMedCrossRef

30.

Yuan L, Sun L, Bo J, et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Annal Transplant : Q Pol Transplant Soc. 2011;16(3):135–8.CrossRef

31.

Mukai HY, Okoshi Y, Shimizu S, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol. 2003;70(6):413–6.PubMedCrossRef

32.

Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12(1):20–5.PubMedPubMedCentralCrossRef

33.

Wang CY, Su WP, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol. 1996;35(1):1–8.PubMedCrossRef

34.

Papenfuss JS, Aoun P, Bierman PJ, Armitage JO. Subcutaneous panniculitis-like T-cell lymphoma: presentation of 2 cases and observations. Clin lymphoma. 2002;3(3):175–80.PubMedCrossRef

35.

Springinsfeld G, Guillaume JC, Boeckler P, Tortel MC, Cribier B. Two cases of subcutaneous panniculitis-like T-cell lymphoma (CD4- CD8+ CD56-). Ann Dermatol Venereol. 2009;136(3):264–8.PubMedCrossRef

36.

Jung HR, Yun SY, Choi JH, Bae SH, Ryoo HM, Kum YS. Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation. Cancer Res Treat : Off J Korean Cancer Assoc. 2011;43(4):255–9.CrossRef

37.

Lee WS, Hwang JH, Kim MJ, et al. Cyclosporine A as a primary treatment for panniculitis-like T cell lymphoma: a case with a long-term remission. Cancer Res Treat : Off J Korean Cancer Assoc. 2014;46(3):312–6.CrossRef

38.

Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma. 2007;7(8):541–5.PubMedCrossRef

39.

Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656–65.PubMedCrossRef

40.

Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407–12.PubMedCrossRef

41.

Takahashi Y, Takata K, Kato S, et al. Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the gammadelta phenotype from Japan. Cancer Sci. 2014;105(7):912–23.PubMedPubMedCentralCrossRef

42.

Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol. 2011;35(8):1214–25.PubMedPubMedCentralCrossRef

43.

Magro CM, Wang X. Indolent primary cutaneous gamma/delta T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol. 2012;138(1):50–6.PubMedCrossRef

44.

Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. J Am Acad Dermatol. 2012;67(4):748–59.PubMedCrossRef

45.

Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology. 2015;67(4):425–41.PubMedCrossRef

46.

Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483–92.PubMedPubMedCentralCrossRef

47.

Beltraminelli H, Mullegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol. 2010;37(1):81–4.PubMedCrossRef

48.

Swick BL, Baum CL, Venkat AP, Liu V. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature. J Cutan Pathol. 2011;38(2):209–15.PubMedCrossRef

49.

Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol. 2010;62(2):300–7.PubMedCrossRef

50.

James E, Sokhn JG, Gibson JF, et al. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk lymphoma. 2015;56(4):951–7.PubMedCrossRef

51.

Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33(1):81–90.PubMedCrossRef

52.

Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31(4):317–22.PubMedCrossRef

53.

Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102(6):2213–9.PubMedCrossRef

54.

Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol : Off J U S Can Acad Pathol Inc. 2008;21(6):708–15.CrossRef

55.

Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol. 2011;12(6):389–401.PubMedCrossRef

56.

Baum CL, Link BK, Neppalli VT, Swick BL, Liu V. Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature. J Am Acad Dermatol. 2011;65(4):739–48.PubMedCrossRef

57.

Suchak R, O’Connor S, McNamara C, Robson A. Indolent CD8-positive lymphoid proliferation on the face: part of the spectrum of primary cutaneous small-/medium-sized pleomorphic T-cell lymphoma or a distinct entity? J Cutan Pathol. 2010;37(9):977–81.PubMedCrossRef

58.

Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.PubMedPubMedCentralCrossRef

59.

Dummer R, Asagoe K, Cozzio A, et al. Recent advances in cutaneous lymphomas. J Dermatol Sci. 2007;48(3):157–67.PubMedCrossRef

60.

Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(12):1581–7.CrossRef

61.

Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–84.PubMedCrossRef

62.

Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139–45.PubMedCrossRef

63.

Zendri E, Venturi C, Ricci R, Giordano G, De Panfilis G. Primary cutaneous plasmacytoma: a role for a triggering stimulus? Clin Exp Dermatol. 2005;30(3):229–31.PubMedCrossRef

64.

May SA, Netto G, Domiati-Saad R, Kasper C. Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. J Am Acad Dermatol. 2005;53(3):512–6.PubMedCrossRef

65.

Aberer E, Fingerle V, Wutte N, Fink-Puches R, Cerroni L. Within European margins. Lancet. 2011;377(9760):178.PubMedCrossRef

66.

Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457–61.PubMedCrossRef

67.

Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000;24(9):1279–85.PubMedCrossRef

68.

Ponzoni M, Ferreri AJ, Mappa S, et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist. 2011;16(11):1582–8.PubMedPubMedCentralCrossRef

69.

Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28(10):502–7.PubMedCrossRef

70.

Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147(6):1147–58.PubMedCrossRef

71.

Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830–41.PubMedCrossRef

72.

Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol. 2006;125(Suppl):S38–49.PubMed

73.

Xie X, Sundram U, Natkunam Y, et al. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod Pathol. 2008;21(6):653–9.PubMedCrossRef

74.

Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002;20(3):647–55.PubMedCrossRef

75.

Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144–50.PubMedCrossRef

76.

Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group [see comments]. Arch Dermatol. 1996;132(11):1304–8.PubMedCrossRef

77.

Geelen FA, Vermeer MH, Meijer CJ, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16(6):2080–5.PubMed

78.

Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662–8.PubMedCrossRef

79.

Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149(6):1183–91.PubMedCrossRef

80.

Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32(3):227–34.PubMedCrossRef

81.

Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722–6.PubMedCrossRef

82.

Streubel B, Scheucher B, Valencak J, et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol. 2006;30(4):529–36.PubMedCrossRef

83.

Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000;95(12):3922–8.PubMed

84.

Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671–8.

85.

Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296–305.PubMedCrossRef

86.

Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Investig Dermatol. 2004;123(1):213–9.PubMedCrossRef

87.

NCCN guidelines. http://www.nccn.org.

88.

Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600–9.PubMedCrossRef

89.

Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8.PubMedCrossRef

90.

Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk lymphoma. 2006;47(5):865–9.PubMedCrossRef

91.

Audigé A, Urosevic M, Schlaepfer E, et al. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J Immunol. 2006;177(9):6227–37.PubMedCrossRef

92.

Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol. 2010;163(1):223–5.PubMed

93.

Burg G, Dummer R, Kerl H. Classification of cutaneous lymphomas. Dermatol Clin. 1994;12(2):213–7.PubMed

94.

Wong KC, Weller PA. Primary cutaneous B cell lymphoma: outcomes and treatment. Australas J Dermatol. 1998;39(4):261–4.PubMedCrossRef

95.

Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136(3):374–8.PubMedCrossRef

96.

Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77(4):300–3.PubMedCrossRef

97.

Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847–53.PubMedCrossRef

98.

Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk lymphoma. 2006;47(9):1902–7.PubMedCrossRef

99.

Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835–44.PubMedCrossRef

100.

Farkas A, Kemeny L, French LE, Dummer R. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol. 2009;22(6):322–34.PubMedCrossRef

101.

Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol : EJD. 2006;16(4):391–3.PubMed

102.

Bogle MA, Riddle CC, Triana EM, Jones D, Duvic M. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol. 2005;53(3):479–84.PubMedCrossRef

103.

Grange F, Wechsler J, Guillaume JC, et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol. 2002;47(4):530–4.PubMedCrossRef

104.

Hofbauer GF, Kessler B, Kempf W, Nestle FO, Burg G, Dummer R. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology. 2001;203(2):168–70.PubMedCrossRef

105.

Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997;36(2):311–4.PubMedCrossRef

106.

Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(14):2258–63.CrossRef

107.

Fenot M, Quereux G, Brocard A, Renaut JJ, Dreno B. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol : EJD. 2010;20(6):753–7.PubMed

Titel: Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
verfasst von: Meenal Kheterpal
Neha Mehta-Shah
Pooja Virmani
Patricia L. Myskowski
Alison Moskowitz
Steven M. Horwitz
Publikationsdatum: 21.04.2016
Verlag: Springer US
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 3/2016
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-016-0322-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies

Nuances in the Management of Older People With Multiple Myeloma

Management of Patients with MYC-Altered Lymphomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie